Qizheng Tibetan Medicine (002287): Implementing the Strongest Pain Core Product Strategy Performance Growth Meets Expectations
Qizheng Tibetan Medicine (002287): Performance is in line with expectations, core product revenue is growing steadily
Qizheng Tibetan Medicine (002287): Performance recovered well and the first quarter ushered in high growth
Qizheng Tibetan Medicine (002287): The impact of the epidemic on the performance of Co., Ltd. is in line with expectations
Qizheng Tibetan Medicine (002287): Performance is beginning to accelerate, and the incentive effect is gradually showing
Qizheng Tibetan Medicine (002287): Performance is in line with expectations and steady growth of core products
Qizheng Tibetan Medicine (002287): Foreign Investment Rating (FIR)
Qizheng Tibetan Medicine (002287): Steady growth in performance and the company's strategy continues to advance
Qizheng Tibetan Medicine (002287): the performance of the company with steady growth of main line varieties is in line with expectations.
Qizheng Tibetan Medicine (002287): steady growth in performance and looking forward to performance for the whole year
Qizheng Tibetan Medicine (002287) Annual report and Quarterly report tracking: during this period, the cost dragged down the performance strategy of "one axis, two wings and three supports" steadily.
Qizheng Tibetan Medicine (002287): steady performance growth "one axis, two wings and three supports" strategy opens
奇正藏药(002287):业绩稳健增长 战略布局逐渐清晰
奇正藏药(002287):股权激励公布 业绩增长可期
奇正藏药(002287):推行股权激励 激励机制逐步完善
奇正藏药(002287)三季报点评:Q3业绩明显提速
奇正藏药(002287)三季报点评:整体业绩稳健 Q3略超预期 销售拓展拉动收入端提速
奇正藏药(002287)中报点评:业绩保持稳定增长 新战略开局之年值得期待
奇正藏药(002287):中报业绩符合预期 核心品种增长稳健
奇正藏药(002287)中报点评:稳定增长 销售渠道不断加强